Abstract
Hyper-activation of nuclear factor kappa B (NF-κB) is germane to carcinogenesis by its fundamental implication in cellular de-differentiation and proliferation, the subversion of apoptosis, the promotion of neoangiogenesis, invasive growth and metastases. Conversely, the expression of multiple nuclear receptors (NRs), arbiters of cellular differentiation, decreases with progressive carcinogenesis. This review is a conceptual discussion of evidence to support NF-κB as the nexus between carcinogenesis and decreased NR expression. Furthermore, it synthesizes the thesis and antithesis of NR function in carcinogenesis and expounds on the functional antagonism between NRs and NF-κB as a basis for the chemopreventive activity of NR ligands. Finally, strategies for optimal chemopreventive interventions with NR ligands are discussed.
Keywords: functional antagonism, nuclear receptors, carcinogenesis, nuclear factor kappa b, neoangiogenesis, nr ligands
Current Cancer Drug Targets
Title: Functional Antagonism between NF-κB and Nuclear Receptors: Implications in Carcinogenesis and Strategies for Optimal Cancer Chemopreventive Interventions
Volume: 4 Issue: 4
Author(s): V. B. Andela
Affiliation:
Keywords: functional antagonism, nuclear receptors, carcinogenesis, nuclear factor kappa b, neoangiogenesis, nr ligands
Abstract: Hyper-activation of nuclear factor kappa B (NF-κB) is germane to carcinogenesis by its fundamental implication in cellular de-differentiation and proliferation, the subversion of apoptosis, the promotion of neoangiogenesis, invasive growth and metastases. Conversely, the expression of multiple nuclear receptors (NRs), arbiters of cellular differentiation, decreases with progressive carcinogenesis. This review is a conceptual discussion of evidence to support NF-κB as the nexus between carcinogenesis and decreased NR expression. Furthermore, it synthesizes the thesis and antithesis of NR function in carcinogenesis and expounds on the functional antagonism between NRs and NF-κB as a basis for the chemopreventive activity of NR ligands. Finally, strategies for optimal chemopreventive interventions with NR ligands are discussed.
Export Options
About this article
Cite this article as:
Andela B. V., Functional Antagonism between NF-κB and Nuclear Receptors: Implications in Carcinogenesis and Strategies for Optimal Cancer Chemopreventive Interventions, Current Cancer Drug Targets 2004; 4 (4) . https://dx.doi.org/10.2174/1568009043332952
DOI https://dx.doi.org/10.2174/1568009043332952 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nuclear Retinoic Acid Receptor Beta as a Tool in Chemoprevention Trials
Current Medicinal Chemistry New Vessel Formation in the Central Nervous System During Tumor Growth, Vascular Malformations, and Moyamoya
Current Neurovascular Research Breast Cancer Diagnosis in Digital Mammography Images Using Automatic Detection for the Region of Interest
Current Medical Imaging TWIST1 Gene: First Insights in Felis catus
Current Genomics Modulation of Expression and Activity of ABC Transporters by the Phytoestrogen Genistein. Impact on Drug Disposition
Current Medicinal Chemistry Modification of Tumor Microenvironment Utilizing Nanotechnology Advancement for Better Therapeutic Effect
Nanoscience & Nanotechnology-Asia Can the Status of the Breast and Ovarian Cancer Susceptibility Gene 1 Product (BRCA1) Predict Response to Taxane-Based Cancer Therapy?
Anti-Cancer Agents in Medicinal Chemistry FBP1, A Tumor Suppressor and Negative Regulator of Glycolysis, was Epigenetically Silenced in Pancreatic Cancer
Current Signal Transduction Therapy Advances and Perspectives in Cancer Nanotherapy: The Added- Value of Nanocarriers
Current Nanomedicine Epidemiological Evidence Associating Secondhand Smoke Exposure with Cardiovascular Disease
Inflammation & Allergy - Drug Targets (Discontinued) Phase I Clinical Trial of Exherin (ADH-1) in Patients with Advanced Solid Tumors
Current Clinical Pharmacology Secretory Leukocyte Protease Inhibitor: More than Just A Protease Inhibitor
Current Immunology Reviews (Discontinued) Development of Thieno[3`,2`:5,6]thiopyrano[4,3-c]pyrazole-3-carboxamide Derivatives as the Estrogen Receptor Ligands: Synthesis, Characterization and Biological Activity
Medicinal Chemistry Significant Role of MUC1 in Development of Resistance to Currently Existing Anti-cancer Therapeutic Agents
Current Cancer Drug Targets Chitosan Nanoparticles as a Carrier for Indigofera intricata Plant Extract: Preparation, Characterization and Anticancer Activity
Current Cancer Therapy Reviews Engineering Simulations for Cancer Systems Biology
Current Drug Targets Identification and Characterization of BRCA1 and BRCA2 Founder Mutations
Current Women`s Health Reviews Gold Nanoparticles in Cancer Therapy: Efficacy, Biodistribution, and Toxicity
Current Pharmaceutical Design Novel Lipid and Polymeric Materials as Delivery Systems for Nucleic Acid Based Drugs
Current Drug Metabolism Delivery Systems for Applications in siRNA Technology
Drug Delivery Letters